Article | October 2, 2018

Strategies For API Solubility And Bioavailability Enhancement: Selecting Technologies And Excipients

Source: Patheon, part of Thermo Fisher Scientific

By Sanjay Konagurthu, Ph. D. Senior Director, Pharma Services Group, Thermo Fisher Scientific, and Tom Reynolds Principal Scientist, Pharma Services Group, Thermo Fisher Scientific.

Strategies For API Solubility And Bioavailability Enhancement: Selecting Technologies And Excipients

Low aqueous solubility is a major problem encountered during the formulation development of drug molecules.  A drug that is not able to dissolve in a patient’s gastrointestinal tract  is unable to be systemically absorbed and, as a result, carries a higher risk of failure during  development.1 Therefore, with about 70 to 90 percent of the drugs in development falling in the two low-solubility classes of the Biopharmaceutical Classification System (BCS),2 it is critical that formulation scientists use the most appropriate solubility enhancement technology and formulation strategies to improve the bioavailability of poorly soluble drugs.

Patheon, part of Thermo Fisher Scientific